Skip to main content

Research Repository

Advanced Search

All Outputs (861)

Cancer screening attendance rates in transgender and gender-diverse patients: a systematic review and meta-analysis (2024)
Journal Article
Chan, A., Jamieson, C., Draper, H., O'Callaghan, S., & Guinn, B. (online). Cancer screening attendance rates in transgender and gender-diverse patients: a systematic review and meta-analysis. BMJ Evidence-Based Medicine, https://doi.org/10.1136/bmjebm-2023-112719

Objectives: To examine disparities in attendance rates at cancer screening services between transgender and gender-diverse (TGD) people in comparison with their cisgender (CG) counterparts, and to determine whether these differences were based on the... Read More about Cancer screening attendance rates in transgender and gender-diverse patients: a systematic review and meta-analysis.

Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology. (2024)
Journal Article
Bonifay, A., Mackman, N., Hisada, Y., Teresa, A., Sachetto, A., Hau, C., Gray, E., Hogwood, J., Aharon, A., Badimon, L., Barile, L., Baudar, J., Beckmann, L., Benedikter, B., Bolis, S., Bouriche, T., Brambilla, M., Burrello, J., Camera, M., Campello, E., …Ja, P. (2024). Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology. Journal of Thrombosis and Haemostasis, https://doi.org/10.1016/j.jtha.2024.05.037

Background: Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in var... Read More about Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology..

Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer? (2024)
Journal Article
Mohamed, E., Fletcher, D., Hart, S., & Guinn, B.-A. (2024). Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?. Onco, 4(2), 87-100. https://doi.org/10.3390/onco4020008

Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors and their discovery rate has been increasing due to enhanced performance of chest CT scans but more than 90% are non-malignant causi... Read More about Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?.

Defining the miRnome of Saphenous Vein Smooth Muscle Cells from Patients with Type 2 Diabetes Mellitus (2024)
Journal Article
Hussain, A., Asare-Amankwah, Y., Qureshi, S., Thornton, M. J., Palmer, T. M., Bolanle, I. O., …Riches-Suman, K. (2024). Defining the miRnome of Saphenous Vein Smooth Muscle Cells from Patients with Type 2 Diabetes Mellitus. Diabetology, 5(2), 178-189. https://doi.org/10.3390/diabetology5020014

Citation: Hussain, A.; Asare-Amankwah, Y.; Qureshi, S.; Thornton, M.J.; Palmer, T.M.; Bolanle, I.O.; Wood, I.C.; Turner, N.A.; Porter, K.E.; Tedder, A.; et al. Defining the miRnome of Saphenous Vein Smooth Muscle Cells from Patients with Type 2 Diabe... Read More about Defining the miRnome of Saphenous Vein Smooth Muscle Cells from Patients with Type 2 Diabetes Mellitus.

Determinants of thermal homeostasis in the preimplantation embryo: a role for the embryo’s central heating system? (2024)
Journal Article
Leese, H. J., & Sturmey, R. G. (2024). Determinants of thermal homeostasis in the preimplantation embryo: a role for the embryo’s central heating system?. Journal of Assisted Reproduction and Genetics, https://doi.org/10.1007/s10815-024-03130-9

A number of factors may impinge on thermal homeostasis in the early embryo. The most obvious is the ambient temperature in which development occurs. Physiologically, the temperature in the lumen of the female tract is typically lower than the core bo... Read More about Determinants of thermal homeostasis in the preimplantation embryo: a role for the embryo’s central heating system?.

Microplastics in human urine: Characterisation using μFTIR and sampling challenges using healthy donors and endometriosis participants (2024)
Journal Article
Rotchell, J. M., Austin, C., Chapman, E., Atherall, C. A., Liddle, C. R., Dunstan, T. S., …Guinn, B.-A. (2024). Microplastics in human urine: Characterisation using μFTIR and sampling challenges using healthy donors and endometriosis participants. Ecotoxicology and environmental safety, 274, Article 116208. https://doi.org/10.1016/j.ecoenv.2024.116208

Microplastics (MPs) are found in all environments, within the human food chain, and have been recently detected in several human tissues. The objective herein was to undertake an analysis of MP contamination in human urine samples, from healthy indiv... Read More about Microplastics in human urine: Characterisation using μFTIR and sampling challenges using healthy donors and endometriosis participants.

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population (2024)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), Article 1085. https://doi.org/10.3390/cancers16061085

To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat... Read More about Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis (2023)
Journal Article
Mohamed, E., García Martínez, D. J., Hosseini, M. S., Yoong, S. Q., Fletcher, D., Hart, S., & Guinn, B. A. (2024). Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis, 45(1-2), Article bgad091. https://doi.org/10.1093/carcin/bgad091

Lung cancer (LC) causes few symptoms in the earliest stages, leading to one of the highest mortality rates among cancers. Low-dose computerised tomography (LDCT) is used to screen high-risk individuals, reducing the mortality rate by 20%. However, LD... Read More about Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis.

Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis (2023)
Journal Article
Batten, L., Sathyapalan, T., & Palmer, T. M. (2023). Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis. International Journal of Molecular Sciences, 24(24), Article 17465. https://doi.org/10.3390/ijms242417465

This review will provide an overview of what is currently known about mechanisms linking poor glycaemic control with increased thrombotic risk. The leading causes of death in people with diabetes are strokes and cardiovascular disease. Significant mo... Read More about Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress (2023)
Journal Article
Connolly, D., Madden, L. A., Edwards, V., D'Oyly, T., Harridge, S., Smith, T., & Lee, V. (2023). Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress. Aerospace Medicine and Human Performance, 94(10), 738-749. https://doi.org/10.3357/AMHP.6247.2023

INTRODUCTION: Consistent blood biomarkers of hypobaric (altitude) decompression stress remain elusive. Recent laboratory investigation of decompression sickness risk at 25,000 ft (7620 m) enabled evaluation of early pathophysiological responses to ex... Read More about Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress.

In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models (2023)
Journal Article
Moris, N., & Sturmey, R. (2023). In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models. Development, 150(17), Article dev202295. https://doi.org/10.1242/dev.202295

Several exciting advances have enabled the derivation of stem cell-based embryo-like models (SCBEMs). Such models allow us to interrogate previously intractable questions in developmental biology and ask hypothesis-driven fundamental questions such a... Read More about In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models.

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide (2023)
Journal Article
Molica, S., Rossi, M., & Allsup, D. (2023). Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide. Acta Haematologica, 147(3), 257-259. https://doi.org/10.1159/000533349

In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus... Read More about Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis (2023)
Journal Article
Morris, V., Ghazi, H., Fletcher, D., & Guinn, B. A. (2023). A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 24(11), Article 9667. https://doi.org/10.3390/ijms24119667

Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation of immature blasts in the bone marrow and peripheral blood. Although AML can occur at any age, the incidence peaks at age 65. The pathobio... Read More about A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells (2023)
Journal Article
Guinn, B. A., Schuler, P. J., Schrezenmeier, H., Hofmann, S., Weiss, J., Bulach, C., …Greiner, J. (2023). A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 24(11), Article 9285. https://doi.org/10.3390/ijms24119285

Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subp... Read More about A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.